Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Obesity (Silver Spring, Md.)|February 25, 2020
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled TrialThomas A Wadden, Jena Shaw Tronieri, Danny Sugimoto, et al.
International Journal of Pharmaceutics|November 27, 2025
Modifying the PSD-95 inhibitor NA-1 for brain delivery through proteolytic stabilization and conjugation to the potentially brain homing peptide BR1Hannah Grønbech Kolberg, Amalie Kjær Andresen, Maria Thaysen, et al.
JAMA Cardiology|November 30, 2022
Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical TrialNicholas H Adamstein, Jan Hein Cornel, Michael Davidson, et al.
Scientific Reports|September 20, 2017
The ClpXP protease is dispensable for degradation of unfolded proteins in Staphylococcus aureusSteen G Stahlhut, Abdulelah A Alqarzaee, Camilla Jensen, et al.
Journal of the American Society of Nephrology : JASN|December 13, 2023
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)Pablo E Pergola, Michael Davidson, Camilla Jensen, et al.
Emerging Microbes & Infections|April 27, 2017
Global and local environmental changes as drivers of Buruli ulcer emergenceMarine Combe, Camilla Jensen Velvin, Aaron Morris, et al.
Plos Neglected Tropical Diseases|January 8, 2019
Comparison of Mycobacterium ulcerans (Buruli ulcer) and Leptospira sp. (Leptospirosis) dynamics in urban and rural settingsMarine Combe, Rodolphe Elie Gozlan, Soushieta Jagadesh, et al.
Frontiers in Molecular Biosciences|June 21, 2021
A Staphylococcus aureus clpX Mutant Used as a Unique Screening Tool to Identify Cell Wall Synthesis Inhibitors that Reverse β-Lactam Resistance in MRSAKristoffer T Bæk, Camilla Jensen, Maya A Farha, et al.
Pageof 3